Tornier: Building an Extremities Play in Orthopedics

For years, investors from private equity firm Warburg Pincus and venture capital firm The Vertical Group contemplated the notion of building an orthopedics business in extremities, a subsegment the big orthopedics players had all but ignored. Now in French orthopedics company, Tornier, they believe they've found the perfect platform. The question is: can they strike gold in an area no one else has been able to mine?

For executives from global private equity firm Warburg Pincus and venture firm The Vertical Group, their first meeting with French orthopedics company Tornier Holdings SAS was far from auspicious. Introduced to the company by investment bankers at Brown Brothers Harriman, Sean Carney and Dick Emmitt, principals at Warburg Pincus and Vertical Group, respectively, flew to Paris in June of 2005 for an introductory meeting with Alain Tornier and his business advisor.

Both investors had heard of Tornier but didn't know much about the company. "It was on our radar screen, but barely," recalls Carney. Tornier, for its part, wasn't conducting an auction, but over the previous several years it had been approached by some of the large orthopedics implant companies about an acquisition and was, with the help of an advisor at Brown Brothers, exploring its options. The investment that both Warburg Pincus and The Vertical Group had jointly made years ago in Wright Medical Group Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By 

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.